GLP-1 Weight-Loss Meds Won't Raise Teens' Suicide Risk, May Even Lower It
MONDAY, Oct. 14, 2024 (HealthDay News) -- As with any new drug, parents and doctors may worry that the use of GLP-1 ...
FDA Reversal on Knockoff GLP-1 Drugs Brings Confusion, and Few Answers
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...
Teens With Obesity Less Likely to Be Suicidal on Weight Loss Drugs: Study
Weight loss drugs like Ozempic were associated with a lower risk of suicidal thoughts in teens with obesity, a new study found.
LifeVantage Introduces the MindBody GLP-1 System™ Transforming Weight Management into a Sustainable Lifestyle
Met With High Demand, the Dual-Product System is Clinically Shown to Increase GLP-1 by 140% on average to Balance Hunger ...
Hosted on MSN1h
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already ...
Anti-obesity drugs tied to lower risk of suicidal thoughts or attempts among young people - study
Researchers said the drugs don’t appear to raise the risk of suicidal thoughts or actions for young people but also urged ...
Impact of medical weight loss on kidney disease
In a recent study explained in Medical News Today, weight loss surgery can significantly decrease the progression of kidney disease.
Cheap Ozempic knock-offs have risen in popularity — but are they safe?
As prices for Ozempic have risen in recent months, many people may be seeking cheaper alternatives for managing diabetes or weight loss. Dr. Brett Osborn and Dr. Sue Decotiis warn of potential risks.
lehifreepress19h
Letter to the Editor: What the public should know about weight-loss medications
Dear Editor, While GLP-1 medications have proven successful in helping people lose weight, some precautions also need to be ...
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs.
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
Developing Long Term Strategies that Matter for Benefits Management
In the ever-changing healthcare landscape, it is crucial to develop sustainable long-term strategies that look beyond ...